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Synthetic Scheme 
3.  Suzuki-Miyaura Coupling 
i.  Oxidative addition of  iodoimidazole (iiia) 
to palladium catalyst - Pd(PPh3)2Cl2 
ii.  Transmetalation of  boronic ester (iiib) 
onto palladium catalyst 
iii.  Reductive elimination, yielding a biaryl (iv) 
Predicted Docking of  C573 at TLR 8 
Conclusions 
Future Work 
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1.  Multicomponent Condensation6 
i.  Aminomalononitrile (ia) adds to activated 
orthoester (ib) 
ii.  Secondary attack by alkyl nucleophile (ic) 
at activated orthoester 
iii.  Intramolecular cyclization driven by the 
aromaticity of  the aminoimdazole (ii) 
2.  Modified Sandmeyer 
i.  Isopentyl nitrite decomposes into 
azanylidyneoxonium and isopentanol 
ii.  Azanylidyneoxonium converts 
aminoimidazole (ii) to diazoimidazole 
iii.  Through a radical intermediate, iodine 
replaces diazonium, yielding (iiia) 
4.  Cyclization 
i.  Intramolecular nucleophillic attack by 
extra cyclic amine onto activated nitrile 
ii.  Tautomerization of  imine intermediate 
driven by aromaticity of  C573 
Figure 5 
Computations of  C573 Docking 
•  Prediction based on X-ray crystallography data 
of  an oxazolequinolone pharmacophore bound 
to TLR 87 
•  C573 was superimposed onto the 
aforementioned pharmacophore and the system 
was relaxed in Pymol (Schrödinger, LLC)  
•  Pymol data was exported to Maestro 
(Schrödinger LLC), converting 3D data into a 
2D map of  residue-ligand interactions 
Predicted Key Interactions 
•  Aromatic overlap between Phe405 and the central ring 
•  Hydrogen bonding between the extra cyclic amine 
and Asp543 as well as Thr574 
•  R2 butyl occupying a hydrophobic pocket consisting 
of  Phe346 and Tyr348 
•  Hydrogen bonding between R1 alkyl heteroatom 
proton donor and Ile349 amide backbone 
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Figure 1 
•  Toll-like receptors 7 and 8 (TLR-7/8) are key 
targets for the development of  autologous 
vaccine adjuvants given their responsiveness to 
s m a l l s y n t h e t i c m o l e c u l e s , s u ch a s 
imadazolequinolines1,2 (Fig. 1).  
•  At the University of  Minnesota, the 
Ferguson Lab has further elucidated the 
relationship between imidazoquinoline 
structure and TLR-7 and 8 activity.  
•  Unpublished structure activity relationships 
(SARs) from the Ferguson Lab indicate 
TLR 8 activity is greatest when R1 is a alkyl 
proton donor. 
Toll like receptor 7 and 8 represent key pharmacological targets in the advancement of  
immunotherapies given their responsiveness to small molecules, such as imidazoquinolines. 
However, in order to develop a potent and efficacious compound it is important to 
disentangle the immunological significance of  TLR 7 vs. TLR 8 agonism. 
Synthesis of  C573 
•  A potential TLR 8 selective agonist with a structure informed by previous SARs 
•  Synthesis proceeded with a 1.3% yield, with the majority of  product lost due to insufficient 
purification, and poor separation of  C573 during the final flash column chromatography 
•  Hypothesized to be a potent autologous vaccine adjuvant (Fig. 2 and 4) 
X-Ray Crystal Predictions 
•  Predicted docking of  C573 with TLR 8, corroborated hypotheses about the binding pocket 
structure based on previous SARs 
•  R2 butyl fits into a hydrophobic pocket, consistent with the TLR 8 SARs for this substituent.  
•  R1 alkyl heteroatom acts as proton donor, consistent with with previous SARs 
•  However, the actual selectivity of  C573 for TLR 8 remains to be empirically verified 
•  Experimentally corroborate TLR 8 x-ray crystallography to determine if  C573 is a 
potent TLR 8 agonist 
 
•  Perform x-ray crystallography on TLR 8 with C573 ligand, to determine the validity 
of  our current TLR8 docking model. 
 
•  Characterize the cytokine production induced by C573, to assess it’s 
immunotherapeutic potential. 
 
•  If  C573 proves to be a TLR 8 selective agonist, then it could be used to determine 
whether or not TLR 8 is active in mice, contrary to accepted hypotheses7 
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Imidazoquinoline 
•  In dendritic cells, TLR-7/8 bind to viral single 
stranded RNA (ssRNA) and induce the 
transcription of  proinflammatory cytokines 
(Fig. 2) which serve many functions in 
stimulating a vigorous immune response to 
pathogens and in some cases, tumor cells3.  
•  Recent publications find TLR 8 agonism is 
greatest when the identity of  R2 is a butyl 
substituent. Additionally, results suggest that 
TLR activity is greatest when a proton donor is 
at the R1 position1.  
•  Therefore, it is of  interest to design a TLR 8 
selective imidazoquinoline that utilizes insights 
about these the three substituents (Fig. 3) 
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Autologous Vaccines 
1.  Cancer cells isolated from the patient 
are lysed to expose antigenic 
biomolecules 
 
2.  Monocytes isolated from the patient 
are differentiated into dendritic cells 
and exposed to tumor antigens 
Figure 29 
Mechanism of  Action 
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TLR 7 TLR 8 Cytokines 
•  TLR 7 and 8 reside in the endosomal 
compartment of  DCs, where they 
bind to viral ssRNA4 
 
•  As adenine analogs, 
Imidazoquinolines also bind to TLR 
7 and/or TLR 8 depending on their 
substituent identities 
 
•  Bound ligand activates TLR 7 and 8, 
which trigger a signal cascade 
initiated by myeloid differentiation 
factor 88 (MyD88). 
 
•  Downstream, the cascade i s 
perpetuated by IKKα,  where the 
pathway extends into the nucleus. 
 
•  Ultimately, transcription factor NF-
κB is activated, allowing the 
production of  proinflammatory 
cytokines. 
 
•  Cytokines include, but are not limited 
to , interferon-α (INF-α), interferon-
γ (INF-γ) and tumor necrosis factor-
α (TNF-α)	
Figure 45 
Dendritic Cell 
3.    Mature dendritic cells presenting 
       tumor antigens are re-injected into 
       the patient as an autologous vaccine 
 
4.    Imidazoquinoline adjuvants are co- 
       injected to increase proinflammatory  
       recruitment by dendritic cells 
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